Table 2.
Baseline (before antiviral therapy) characteristics of all DAAs and PR SVR patients.
| DAAs | PR | P value | |
|---|---|---|---|
| n | 484 | 757 | |
| Age (yr) | 50.6 ± 13.8 | 49.9 ± 11.7 | 0.283 |
| Male sex (n, %) | 225 (46.5) | 334 (44.1) | 0.448 |
| BMI (kg/m2) | 23.7 ± 3.3 | 23.5 ± 3.2 | 0.307 |
| NAFLD (n, %) | 131 (27.1) | 186 (24.6) | 0.359 |
| Genotype (%) | 0.768 | ||
| 1b | 353 (72.9) | 541 (71.5) | |
| 2a | 123 (25.4) | 200 (26.4) | |
| others | 8 (1.7) | 16 (2.1) | |
| HCV RNA (Log10 IU/ml) | 6.1 ± 1.2 | 6.0 ± 1.1 | 0.335 |
| ALT (U/L) | 74.6 ± 15.9 | 75.2 ± 15.5 | 0.540 |
| TBIL (μmol/L) | 20.3 ± 8.9 | 20.9 ± 9.4 | 0.337 |
| CRE (μmol/L) | 74.0 ± 15.0 | 74.0 ± 13.0 | 0.990 |
| PLT ( × 109/L) | 161.0 ± 67.0 | 162.0 ± 61.1 | 0.802 |
| Age ≥ 55 yr (n, %) | 195 (40.3) | 288 (38.0) | 0.465 |
| AFP ≥ 20 ng/ml (2 × ULN) | 104 (21.5) | 150 (19.8) | 0.522 |
| Diabetes (n, %) | 41 (8.5) | 75 (9.9) | 0.455 |
| LSM ≥ 14.6 kPa (n, %) | 151 (31.2) | 225 (29.7) | 0.625 |
| Mean LSM (kPa) | 11.6 (7.4–16.4) | 10.7 (7.6–15.8) | 0.212 |
| Follow-up time (months) | 48.0 (43.5–50.0) | 48.0 (44.5–49.0) | 0.065 |
Continuous variables were expressed as mean ± sd and compared using the unpaired, 2-tailed t-test. Categorical variables were presented as numbers and percentages and compared using the chi-square test.